Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03999515
Title Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

prostate adenocarcinoma

Therapies

Enzalutamide + Erdafitinib

Abiraterone + Erdafitinib

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.